2. Search Result
Search Result
Results for "

Tauopathy

" in MedChemExpress (MCE) Product Catalog:

39

Inhibitors & Agonists

5

Peptides

3

Inhibitory Antibodies

8

Antibodies

3

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B0478
    Trazodone hydrochloride
    5+ Cited Publications

    AF-1161

    		 5-HT Receptor Serotonin Transporter Histamine Receptor Adrenergic Receptor Neurological Disease
    Trazodone hydrochloride (AF-1161) is a triazolopyridine derivative that belongs to the class of serotonin receptor antagonists and reuptake inhibitors (SARIs). Trazodone hydrochloride has anti-depressant and anti-insomnious activity. Trazodone hydrochloride exerts antagonistic properties against a1- and a2-adrenergic receptors and histamine H1 receptors, with minimal anticholinergic effects .
    Trazodone hydrochloride
  • HY-134850
    QC-01–175

    		PROTACs Tau Protein Neurological Disease
    QC-01-175 is a heterobifunctional molecule, which degrades aberrant tau. QC-01-175 reduces the levels of A152T and P301L mutant tau protein and protects neurons from tau-mediated toxicity and improve cell survival (Pink: ligand for target protein Aberrant tau ligand 1 (HY-W453397); Black: linker NH2-PEG3 (HY-W007545); Blue: ligand for E3 ligase Pomalidomide (HY-10984)) .
    QC-01–175
  • HY-134968
    TTBK1-IN-1
    1 Publications Verification

    		 Tau Protein Neurological Disease
    TTBK1-IN-1 is a potent, selective and brain-penetrant tau tubulin kinase 1 (TTBK1) inhibitor with an IC50 of 2.7 nM. TTBK1-IN-1 can be used for the research of alzheimer’s disease and related tauopathies . TTBK1-IN-1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    TTBK1-IN-1
  • HY-D0961
    Gallocyanine chloride

    		Fluorescent Dye Wnt β-catenin Neurological Disease Inflammation/Immunology Cancer
    Gallocyanine chloride is a synthetic blue dyestuff that can be used as a potential agent for the research of Alzheimer's disease and related neurodegenerative tauopathies. Gallocyanine chloride inhibits DKK1/LRP6 interaction (IC50=6.38 μM), activates Wnt signaling pathway, and causes β-catenin accumulation. Gallocyanine chloride exhibits anti-metastasis, anti-inflammatory and anti-fibrosis activities. Gallocyanine chloride can be used as a fluorescent probe for detection of superoxide anion radicals .
    Gallocyanine chloride
  • HY-W143216
    Azure C

    Monomethylthionine

    		 Amyloid-β Tau Protein Neurological Disease
    Azure C acts as a tau oligomer modulator and Aβ42 oligomerization inhibitor. It regulates hsp70 ATPase activity, thereby mediating the clearance of tau protein. Azure C reduces the levels of toxic tau oligomers by promoting the formation of non-toxic tau aggregates, rescues neuroblastoma cells from tau oligomer-induced toxicity, and binds to and inhibits Aβ42 oligomerization without suppressing its fibrillization. Azure C is generated via sequential oxidation of methylene blue or Azure B through a horseradish peroxidase-mediated reaction, and accumulates in HRP reaction media. Azure C can be used in studies related to tauopathies, including Alzheimer's disease .
    Azure C
  • HY-161307
    T-518

    		HDAC Microtubule/Tubulin Neurological Disease
    T-518 is an orally active, BBB-penetrant and potent DFMO-based HDAC6 inhibitor with high selectivity (IC50 = 36 nM). T-518 improves axonal transport. T-518 ameliorates object recognition deficit. T-518 can be studied in research for Alzheimer’s disease and tauopathy .
    T-518
  • HY-144681
    Ceperognastat

    LY3372689

    		 OGA Tau Protein Neurological Disease
    Ceperognastat (LY3372689) is an orally active O-GlcNAcase (OGA) enzyme inhibitor. Ceperognastat can be used for tauopathies research, including Alzheimer’s disease .
    Ceperognastat
  • HY-132582C
    Diranersen sodium

    IONIS-MAPTRx sodium; BIIB080 sodium; ISIS 814907 sodium

    		 Tau Protein Neurological Disease
    Diranersen (IONIS-MAPTRx) sodium is an antisense oligonucleotide that targets the human MAPT gene to inhibit the production of tau protein. Diranersen sodium can be used in research related to Alzheimer's disease and tauopathies .
    Diranersen sodium
  • HY-156586
    Egalognastat

    ASN90

    		 OGA Tau Protein Neurological Disease
    Egalognastat (ASN90) is a selective, brain-penetrant and orally active O-GlcNAcase (OGA) enzyme inhibitor with an IC50 value of 10.2 nM. Egalognastat increases O-GlcNAcylation of intracellular proteins like tau and α-synuclein, preventing their aggregation and toxicity. Egalognastat does not inhibit hexosaminidase (Hex). Egalognastat can be used for the research of neurodegenerative diseases, such as tauopathies and α-synucleinopathies (e.g., Alzheimer’s disease and Parkinson’s disease) .
    Egalognastat
  • HY-P10861A
    RI-AG03 acetate

    		Tau Protein Neurological Disease
    RI-AG03 acetate is a proteolytically stable tau aggregation inhibitor that crosses the blood-brain barrier and exhibits oral efficacy. RI-AG03 acetate inhibits tau aggregation and promotes the formation of alternative amorphous aggregates that are non-amyloidogenic. RI-AG03 acetate mediates cellular uptake through direct membrane penetration and macropinocytosis, and its conjugation with cell-penetrating peptide sequences (CPPs) enhances the binding of cells to liposomes. RI-AG03 acetate suppresses aggregation-dependent neurodegenerative and behavioral phenotypes, and extends the lifespan of Drosophila models of tauopathy. RI-AG03 acetate can be used for research on tau-related diseases such as Alzheimer's disease .
    RI-AG03 acetate
  • HY-137557
    Florzolotau

    APN1607; PM-PBB3

    		 Tau Protein Neurological Disease
    Florzolotau (APN1607) is a positron emission tomography (PET) ligand that can be used for the detection of Alzheimer's disease (AD) and other tau proteinopathies. Its binding sites are located in the β-sheet of paired helical filaments (PHFs) and straight filaments (SFs) of tau protein, as well as in the C-shaped cavity of SFs. In addition, APN-1607 binds to intraneuronal inclusions in Alzheimer's disease (AD), primary age-related tauopathy (PART) and posterior cortical atrophy (PCA). Florzolotau shows promise for PET imaging studies of neurological disorders, particularly tau proteinopathies .
    Florzolotau
  • HY-132582
    Diranersen

    IONIS-MAPTRx; BIIB080; ISIS 814907

    		 Tau Protein Neurological Disease
    Diranersen (IONIS-MAPTRx) is an antisense oligonucleotide that targets the human MAPT gene to inhibit the production of tau protein. Diranersen can be used in research related to Alzheimer's disease and tauopathies .
    Diranersen
  • HY-P99163
    Tilavonemab

    ABBV-8E12; C2N-8E12

    		 Tau Protein Neurological Disease
    Tilavonemab (ABBV-8E12) is a humanized anti-tau monoclonal antibody that binds to amino acids 25-30 near the N-terminus of the tau protein. Tilavonemab can block the ability of human and mouse neurons to uptake tau aggregates. Tilavonemab can be used for research on Alzheimer’s disease and other tauopathies .
    Tilavonemab
  • HY-174311
    GT-02216

    		Glycosidase Neurological Disease Metabolic Disease
    GT-02216 can bind to GCase allosterically and enhance its activity. GT-02216 enhances the activity of GCase in primary human fibroblasts dose-dependently reduces the accumulation of its substrate, hexosylsphingosine (HexCer). GT-02216 reduces the Tau accumulation in mutant GBA1 fibroblasts. GT-02216 can be used for the study of Parkinson’s disease .
    GT-02216
  • HY-P10861
    RI-AG03

    		Tau Protein Neurological Disease
    RI-AG03 is a proteolytically stable tau aggregation inhibitor that crosses the blood-brain barrier and exhibits oral efficacy. RI-AG03 inhibits tau aggregation and promotes the formation of alternative amorphous aggregates that are non-amyloidogenic. RI-AG03 mediates cellular uptake through direct membrane penetration and macropinocytosis, and its conjugation with cell-penetrating peptide sequences (CPPs) enhances the binding of cells to liposomes. RI-AG03 suppresses aggregation-dependent neurodegenerative and behavioral phenotypes, and extends the lifespan of Drosophila models of tauopathy. RI-AG03 can be used for research on tau-related diseases such as Alzheimer's disease .
    RI-AG03
  • HY-148112
    Casein kinase 1δ-IN-1

    		Casein Kinase Neurological Disease
    Casein kinase 1δ-IN-1 is an inhibitor of casein kinase 1δ (CK1δ). Casein kinase 1δ-IN-1 can be used for the research of neurodegenerative diseases such as tauopathies .
    Casein kinase 1δ-IN-1
  • HY-151335
    KU-177

    		HSP Cancer
    KU-177 is a potent inhibitor of Hsp90 ATPase homologue 1 (Aha1), ablates Aha1-driven enhancement of Hsp90-dependent tau aggregation. KU-177 also disrupts Aha1/Hsp90 interactions (IC50=4.08 μM) without inhibition of Hsp90’s ATPase activity. KU-177 can be used for tauopathies research .
    KU-177
  • HY-P4943
    Tau Peptide (273-284)

    		Tau Protein Neurological Disease
    Tau Peptide (273-284) is a Tau fragment. Tau Peptide (273-284) can be used in the research of tauopathies, especially Alzheimer's disease .
    Tau Peptide (273-284)
  • HY-W046071
    N-Boc-trans-4-fluoro-L-proline

    		Drug Intermediate Others
    N-Boc-trans-4-fluoro-L-proline is a non-natural amino acid substitute used to construct monoclonal antibodies that specifically target the seed conformation of tau protein .
    N-Boc-trans-4-fluoro-L-proline
  • HY-176540
    Microtubule stabilizer-1

    		Microtubule/Tubulin Neurological Disease
    Microtubule stabilizer-1 (compound 69) is a brain-penetrant microtubule (MT) stabilizer. Microtubule stabilizer-1 increases acetylated α-tubulin (AcTub) levels and prevents the characteristic loss of neuronal MTs that is observed after incubation with Okadaic acid (HY-N6785). Microtubule stabilizer-1 can be used for the study of Alzheimer’s disease (AD) and related neurodegenerative tauopathies .
    Microtubule stabilizer-1
  • HY-154987
    MARK4 inhibitor 3

    		MARK Cancer
    MARK4 inhibitor 3 (compound 23b) is an inhibitor of MARK4 with an IC50 value of 1.01 μM. MARK4 inhibitor 3 inhibits cancer cells growth. MARK4 inhibitor 3 can be used for research on cancer and tauopathies .
    MARK4 inhibitor 3
  • HY-162712
    OX-201

    		Orexin Receptor (OX Receptor) Tau Protein Neurological Disease
    OX-201 is an orally active, blood-brain barrier-permeable OX2R agonist with an EC50 of 8.0 nM. OX-201 activates OX2R to induce wakefulness and neuronal activation. OX-201 promotes the release of neuron activity-dependent tau protein from neurons into the interstitial fluid of hippocampal tissues. OX-201 is applicable to research related to Alzheimer's disease and tauopathies .
    OX-201
  • HY-W835959
    ACI-3024

    		Tau Protein Neurological Disease
    ACI-3024 is an an orally active and highly selective Tau protein aggregation inhibitor. ACI-3024 decrease the β-sheet content and seeding properties of pathological Tau from different Tauopathies, leading to a significant rescue of the Tau-induced neurodegeneration and neuroinflammation in a cellular model. ACI-3024 is promising for research of neurodegenerative diseases .
    ACI-3024
  • HY-116279
    JG-48

    		HSP Neurological Disease
    JG-48 is a Hsp70 inhibitor that can reduce tau levels in models of tauopathy .
    JG-48
  • HY-179377
    Aha1/Hsp90-IN-2

    		HSP Tau Protein Neurological Disease
    Aha1/Hsp90-IN-2 is a selective inhibitor of the Hsp90/Aha1 interaction, with its IC50 being 1.46 μM. Aha1/Hsp90-IN-2 inhibits the activation of Hsp90 ATPase activity mediated by Aha1 by specifically blocking the binding of Hsp90 to Aha1, thereby reducing tau protein aggregation. Aha1/Hsp90-IN-2 can be used for the study of neurodegenerative diseases, such as Alzheimer's disease .
    Aha1/Hsp90-IN-2
  • HY-147321
    3'-DMTr-dG(iBu)

    		Tau Protein HBV Infection Neurological Disease
    3'-DMTr-dG(iBu) is a nucleoside for the synthesis of nucleic acid, such as antiviral agents used in the research of viral infection (HBV, HDV), and oligonucleotides against Alzheimer’s disease and other tauopathies .
    3'-DMTr-dG(iBu)
  • HY-P4610
    H-Trp-Tyr-OH

    		GLP Receptor Metabolic Disease
    H-Trp-Tyr-OH is an orally active tryptophan-tyrosine dipeptide with blood-brain barrier permeability. H-Trp-Tyr-OH exerts physiological regulatory effects by stimulating enteroendocrine cells to secrete glucagon-like peptide GLP-1. In mouse models of tauopathies, H-Trp-Tyr-OH inhibits tau phosphorylation, reduces the level of neurofibrillary tangles, increases dopamine turnover, upregulates synapsin expression, and elevates cecal short-chain fatty acid levels, thereby improving behavioral deficits and extending lifespan. H-Trp-Tyr-OH can be used in research related to impaired glucose tolerance and tauopathies .
    H-Trp-Tyr-OH
  • HY-134968A
    (R)-TTBK1-IN-1

    		Tau Protein Neurological Disease
    (R)-TTBK1-IN-1 is a potent, selective and brain-penetrant tau tubulin kinase 1 (TTBK1) inhibitor. (R)-TTBK1-IN-1 is an enantiomer of TTBK1-IN-1 (HY-134968). (R)-TTBK1-IN-1 can be used in the research of alzheimer’s disease and related tauopathies . (R)-TTBK1-IN-1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    (R)-TTBK1-IN-1
  • HY-120744
    LDN-193665

    		Tau Protein Others
    LDN-193665 is a Tau kinase inhibitor with tauopathy-modifying activity. LDN-193665 inhibits Tau phosphorylation, improves tauopathy in animal models, reduces Sarkosyl-insoluble Tau, and restores memory. It may be necessary to simultaneously target multiple kinases to effectively inhibit tauopathies.
    LDN-193665
  • HY-176936
    Tau-aggregation-IN-5

    		Tau Protein Neurological Disease
    Tau-aggregation-IN-5 is a Tau-aggregation inhibitor (EC50 = 0.31 μM). Tau-aggregation-IN-5 targets P4HB covalently and activates mild ER stress. Tau-aggregation-IN-4 can be used for the study of neurodegenerative disorders such as Alzheimer’s and Pick’s diseases .
    Tau-aggregation-IN-5
  • HY-178927
    Tau-aggregation-IN-4

    		Tau Protein Neurological Disease
    Tau-aggregation-IN-4 is a Tau-aggregation inhibitor (EC50 = 2.99 μM). Tau-aggregation-IN-4 can be used for the study of neurodegenerative disorders such as Alzheimer’s and Pick’s diseases .
    Tau-aggregation-IN-4
  • HY-181619
    TAO Kinase-IN-3

    		MAP3K Neurological Disease Metabolic Disease Cancer
    TAO Kinase-IN-3 is a potent pan-TAOK (Thousand-And-One Kinase) inhibitor that specifically binds to and inhibits the kinase activities of TAOK1, TAOK2 and TAOK3 with Kd values of <0.17 nM, 0.34 nM, and 0.17 nM, respectively. TAO Kinase-IN-3 can be used to study Alzheimer's disease, primary tauopathies and related syndromes. In addition, TAO Kinase-IN-3 is also widely used in research on the mechanisms of cancer cachexia and the muscle atrophy it induces .
    TAO Kinase-IN-3
  • HY-P992172
    ADEL-Y01

    		Tau Protein Neurological Disease
    ADEL-Y01 is a humanized and parental murine blood-brain barrier-penetrating monoclonal antibody against tau-acK280. ADEL-Y01 specifically recognizes tau-acK280 and its surrounding residues, mediates the neutralization and phagocytosis of acetylated tau aggregates, and interferes with the activity of pathological tau protein. ADEL-Y01 prevents the progression of tauopathies, increases neuronal survival rate, reduces tau-related pathological changes, and improves memory impairment. ADEL-Y01 can be used in research related to Alzheimer's disease and tauopathies .
    ADEL-Y01
  • HY-181281
    VU6080195

    		Ser/Thr Kinase Neurological Disease Cancer
    VU6080195 is a blood-brain barrier-permeable pan-TAOK activator. VU6080195 shows the highest potency against TAOK1 (EC50 = 270 nM), followed by TAOK3 (EC50 = 503 nM) and TAOK2 (EC50 = 1,376 nM). VU6080195 can be used for the research of diseases such as neurodevelopmental disorders, tauopathies and breast cancer .
    VU6080195
  • HY-181280
    VU6083859

    		Ser/Thr Protease Neurological Disease
    VU6083859 is a blood-brain barrier-permeable TAOK1 inhibitor with an IC50 of 158 nM. VU6083859 selectively inhibits TAOK1, exhibits only weak or no activity against TAOK2 and TAOK3, and shows high selectivity for a variety of other kinases. VU6083859 is applicable to research related to neurodevelopmental disorders and tauopathies.
    VU6083859
  • HY-183584
    ARN25699

    		GSK-3 Src DYRK Tau Protein Microtubule/Tubulin Neurological Disease
    ARN25699 is a kinase inhibitor with an IC50 of 5.5 nM against GSK-3β, 2.2 nM against FYN-α, and 242.3 nM against DYRK1A, and it exhibits oral bioavailability. ARN25699 reduces hyperphosphorylation of tau protein and promotes microtubule bundle formation. ARN25699 has a broader kinome inhibitory profile and targets kinases associated with the pathogenic mechanisms linked to Alzheimer's disease. ARN25699 can be used in the research of Alzheimer's disease and related tauopathies .
    ARN25699
  • HY-186130
    CAST-calpain-2 stabilizer-1

    		Calpain Neurological Disease
    CAST-calpain-2 stabilizer-1 is a blood-brain barrier permeable stabilizer of CAST-calpain-2 interaction. CAST-calpain-2 stabilizer-1 shows no activity against GSK3. CAST-calpain-2 stabilizer-1 can be used in the research of Huntington's disease and tauopathies .
    CAST-calpain-2 stabilizer-1
  • HY-137557A
    (E/Z)-Florzolotau

    (E/Z)-APN1607; (E/Z)-PM-PBB3

    		 Tau Protein Neurological Disease
    (E/Z)-Florzolotau ((E/Z)-APN1607) is a mixed configuration or unspecified configuration of Florzolotau (HY-137557). Florzolotau (APN1607) is a positron emission tomography (PET) ligand that can be used for the detection of Alzheimer's disease (AD) and other tau proteinopathies. Its binding sites are located in the β-sheet of paired helical filaments (PHFs) and straight filaments (SFs) of tau protein, as well as in the C-shaped cavity of SFs. In addition, APN-1607 binds to intraneuronal inclusions in Alzheimer's disease (AD), primary age-related tauopathy (PART) and posterior cortical atrophy (PCA). Florzolotau shows promise for PET imaging studies of neurological disorders, particularly tau proteinopathies .
    (E/Z)-Florzolotau
  • HY-P99648A
    Gosuranemab (powder)

    BMS-986168 (powder); IPN007 (powder); BIIB092 (powder)

    		 Tau Protein Neurological Disease
    Gosuranemab (BMS-986168; IPN007; BIIB092) (powder) is a humanised IgG4 anti-tau monoclonal antibody. Gosuranemab (powder) neutralizes the extracellular tau protein, inhibiting the spread and aggregation of pathological tau protein. Gosuranemab (powder) can be used for the research of progressive supranuclear palsy and early Alzheimer’s disease .
    Gosuranemab (powder)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: